Galectins are glycan-binding proteins implicated in intracellular signaling, cell–cell communication, cellular proliferation and survival. These endogenous lectins have emerged as key players in the tumor microenvironment. They are expressed and released by different cell types, including tumor, stromal, endothelial and immune cells. Galectins critically influence tumor progression by modulating tumor cell migration, invasiveness, angiogenesis and antitumor immune responses. Intracellularly, galectins modulate survival and proliferation and they interact with a variety of signaling pathways. Given these extracellular and intracellular functions and their regulated expression at sites of tumor growth and metastasis, galectins have stimulated great interest as relevant biomarkers and novel targets in cancer therapy.
The information surveyed in this volulme is designed to provide the clinician with an expert overview of the current state of the art in breast cancer management. It should provide at least a flavor of the major paradigm shift that is occurring in this rapidly evolving field. Breast cancer management is moving away from a "kill or cure" model and advancing toward a model focused on strategies of prevention and of long-term management of breast cancer as a chronic disease. The acceptance of this new paradigm by patients and clinicians alike will represent a major focus for the twenty-first century.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.